| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.054 | 0.4 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | VAF-347 | CTRPv2 | pan-cancer | AAC | -0.041 | 0.4 |
| mRNA | BRD-K37390332 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | cyanoquinoline 11 | CTRPv2 | pan-cancer | AAC | 0.045 | 0.4 |
| mRNA | TGX221 | GDSC1000 | pan-cancer | AAC | -0.042 | 0.4 |
| mRNA | LY-2157299 | CTRPv2 | pan-cancer | AAC | -0.071 | 0.4 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | MLN4924 | GDSC1000 | pan-cancer | AAC | 0.034 | 0.4 |
| mRNA | BRD-K28456706 | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |